Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
TRAIL-R2 (DR5) Recombinant Rabbit Monoclonal Antibody (102)
FIGURE: 1 / 1
TRAIL-R2 (DR5) Antibody (MA5-29606) in Flow
Product Details
MA5-29606
Species Reactivity
Host/Isotype
Expression System
Class
Type
Clone
Immunogen
Conjugate
Form
Concentration
Purification
Storage buffer
Contains
Storage conditions
Shipping conditions
RRID
Product Specific Information
This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%).
Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
This antibody has specificity for Human TNFRSF10B/TRAILR2/CD262/DR5.
Target Information
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Bioinformatics
Protein Aliases: apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; dr-5; Fas-like protein; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF-related apoptosis-inducing ligand receptor 2; TRAIL receptor 2; Tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9
Gene Aliases: CD262; DR5; KILLER; KILLER/DR5; TNFRSF10B; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; UNQ160/PRO186; ZTNFR9
UniProt ID: (Human) O14763
Entrez Gene ID: (Human) 8795
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support